PrandiMet is a combination drug that encompasses Prandin and metformin to treat Type 2 diabetes.
Type 2 diabetic patients have a new drug to treat their disease. It’s PrandiMet (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (Prandin, Novo Nordisk) and insulin sensitizer, metformin. The combination drug is designed to lower the blood glucose of Type 2 diabetics whose hyperglycemia cannot be controlled by meglitinide and/or metformin. To be marketed by Sciele Pharma, the drug will be available in two dosage strengths-1 mg (repaglinide)/500mg (metformin) and 2 mg (repaglinide)/500 mg (metformin)-for administration at two to three times a day with meals.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.